ArticleCancer immunology, immunotherapy : CII2026
Clinical characteristics, prognostic factors, and feasibility of ICI continuation in immune checkpoint inhibitor-related pneumonitis.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Response to pembrolizumab after progression on durvalumab in cholangiocarcinoma: a case report of immune checkpoint inhibitor switching.Clinical journal of gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeImmune checkpoint inhibitor (ICI)-related pneumonitis (ICI-pneumonitis) is a serious complication, whose clinical course and optimal management strategies remain inadequately elucidated. This study clarified whether post-pneumonitis ICI continuation is safe and feasible, identified risk factors for fatal outcomes or successful continuation, and assessed whether findings from patients with lung cancer can be generalized to those with other malignancies.
methodsThis retrospective study analyzed data from 1,320 patients who received ICI therapy at Kyushu University Hospital between September 2014 and March 2023. Among these, 300 and 1,020 patients had lung and non-lung cancers, respectively. Clinical characteristics, treatment strategies, and outcomes were compared between the two groups. Predictors of fatal pneumonitis and successful ICI continuation were identified using univariable logistic regression.
resultsICI-pneumonitis occurred in 96 (7.3%) patients, with a higher incidence in those with lung cancer (14.0%, [42/300]) than in those with non-lung cancers (5.3%, [54/1020]). Clinical characteristics remained similar across cancer types post-pneumonitis. Diffuse alveolar damage pattern, grade ≥ 3 pneumonitis at diagnosis, and elevated C-reactive protein level were significant predictors of fatal pneumonitis. Among 34 patients who attempted ICI continuation, 20 (58.8%) maintained ICI treatment until disease progression. Successful ICI continuation showed a trend toward association with normal baseline lung parenchyma.
conclusionsThe similar characteristics of ICI-pneumonitis across malignancies support the generalizability of management strategies. Approximately one-fifth of patients successfully continued ICI therapy after pneumonitis. Systematic radiological surveillance and appropriate severity-based treatment may help optimize outcomes in patients receiving ICI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.